PHI News Room
All News and Press Releases
Enter any phrase or word you would like to search for and click .
PostNews: Press Release
Phase Holographic Imaging Announces Next Generation HoloMonitor
Phase Holographic Imaging (PHI) is pleased to announce that the next generation of PHI’s live cell imaging system enters its final development stage. The new model is currently undergoing pre-production testing both internally and externally at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine.
PostNews: Press Release
Phase Holographic Imaging Announces Management Changes
Recent technical progress has led the Board of Directors of Phase Holographic Imaging (PHI) to decide to focus resources on the company’s clinical product development program. In relation to this, the Board of Directors has, in discussion with CEO Anders Månsson, decided to initiate the search for a new CEO to lead the ambitious development that lies ahead.
PostNews: Press Release
PHI announces last day of trading in BTA
PostNews: Press Release
Bulletin from the annual general meeting of Phase Holographic Imaging PHI AB (publ) 8 January 2025
Phase Holographic Imaging PHI AB (publ), held a general meeting on 8 January 2025. The following resolutions were made.
PostNews: Press Release
PHI announces outcome of rights issue
PostNews: Press Release
Founder and board member subscribes for shares in the ongoing rights issue
Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB has notified the Company that he, together with closely related parties, follows Altium SA’s lead by subscribing for shares in the Company’s ongoing fully secured rights issue. The subscription amounts to approximately 300 TSEK.
Company News
Here, you see PHI featured in recent news and find previous CEO commentaries.
BioStock: Studio interview with Anders Månsson and Goran Dubravčić
Recently, PHI welcomed Anders Månsson as its new CEO. In a video interview, Månsson and Chairman of the Board Goran Dubravčić discuss the company’s future strategy and the ongoing rights issue.
BioStock: PHI’s new CEO: “I am excited to lead us forward with new energy”
Anders Månsson was recently appointed CEO of Phase Holographic Imaging. With extensive leadership experience in the international life sciences sector, he aims to expand PHI’s global reach and position the company as a leader in non-invasive cell quality control technologies. BioStock spoke with him about his vision for the future.
BioStock: PHI accelerates growth with record order
PHI recently received its most significant order from Altium, comprising 20 HoloMonitor systems and additional components. This milestone aligns with the positive growth trajectory since the start of the year. PHI is also approaching the final exercise day of their TO 4 warrants on October 3, raising up to SEK 6.2 million before issue costs. BioStock reached out to CEO Patrik Eschricht for a comment.
BioStock: PHI’s CEO comments on the approved US listing
PHI has been approved for a dual US listing in addition to its primary listing on the Swedish Spotlight market. What does this mean for the company’s shareholders, and how might it impact the company’s long-term valuation? BioStock reached out to PHI’s CEO Patrik Eschricht to discuss this and the upcoming redemption of the TO4 warrants that could potentially raise SEK 20.8 million in October.
